30 results about "Choroid Neoplasm" patented technology

The invention discloses a Chinese medicinal composition for treating malignant tumor, belonging to the field of Chinese medicines. The Chinese medicinal composition is a medicament preparation formed from herba oldenlandiae, astragalus root, tuckahoe, prepared pinellia tuber, herba scutellariae barbatae, teloon, scorpion, scolopendra and the like by adopting advanced processes including extraction with water, extraction with ethanol, enzymolysis of trypsinase and the like according to a certain compatible requirement, and the medicament preparation is preferably prepared into capsules and tablets. The Chinese medicinal composition has a certain function for relieving symptoms for lung cancer, liver cancer, gastric cancer, intestinal cancer, breast cancer, encephaloma, lymph cancer and other malignant tumors, reducing tumor bodies, inhibiting the growth of the tumors and the like; and according to the Chinese medicinal composition, the human immune capability can be improved, the lives of patients suffered from tumors can be prolonged and the adverse reactions of leukocytopenia, dizzy, weakness and fatigue, skinniness, poor appetite, nausea and vomiting and the like due to radiotherapy chemotherapy for cancers can be effectively relieved.

The invention relates to the use of a combination of cannabinoids, particularly tetrahydrocannabinol (THC) and cannabidiol (CBD), in the manufacture of a medicament for use in the treatment of cancer. In particular the cancer to be treated is a brain tumour, more particularly a glioma, more particularly still a glioblastoma multiforme (GBM).

The present invention relates to compounds with a structure shown as a formula I or pharmaceutically acceptable salts thereof. R1, R2, R3, R4, R5 and R6 are defined as in the specification. The invention also provides a preparation method of the compounds with a structure shown as the formula I or pharmaceutically acceptable salts thereof, pharmaceutical compositions containing the compounds and pharmaceutically acceptable salts thereof, and application of betulinic acid analogues or solvates thereof as active ingredients to preparation of antineoplastic medicaments for treating lung cancer, prostate cancer, colon cancer, leukemia, breast cancer, liver cancer, gastric cancer, pancreatic cancer, human malignant glioma and brain tumor.

There is provided a compound of formula I or a pharmacologically acceptable salt thereof:for use in the treatment of a brain cancer selected from a MGMT positive astrocytic brain tumor, a metastatic brain cancer and primary CNS lymphoma and a method of treating said brain cancers in a patient in need thereof comprising administering to the patient said compound of formula I or a pharmacologically acceptable salt thereof.

The invention relates to an application of a tanshinone compound in preparing anti-tumor medicaments, and the prepared medicaments can resist tumors, such as brain tumors, lung cancer, liver caner, breast cancer, prostatic cancer, pancreatic cancer, cervical cancer, gastric cancer, esophagus cancer, and the like. Proved by experiments, the tanshinone compound is concentration-dependent to suppress the proliferation of tumor cells. The compound can obviously induce the expression of quinone reductase and obviously suppress the generation of tumor vessels, thus the compound can also be used for preparing cancer chemical prevention medicaments, anti-inflammatory medicaments and medicaments for suppressing the generation of the tumor vessels. Frequently used low-price reagents, such as alcohol, chloroform, methanol, silica gel, and the like, are used for separating tanshinone compound monomers from medicinal materials. The method is simple and reliable, has low cost and high efficiency, can be used for carrying out industrialized mass production and is beneficial to popularization and application. The tanshinone compound has a structural general formula disclosed in the specification.

Methods and compositions suitable for the treatment of malignancies such as recurrent glioma and progressive secondary brain tumor are disclosed. These methods employ a hexitol derivative such as dianhydrogalactitol, a derivative or analog of dianhydrogalactitol, diacetyldianhydrogalactitol, or a derivative or analog of diacetyldianhydrogalactitol. The compositions can include such hexitol derivatives.

The invention relates to a pharmaceutical composition having apiolin and apiolin derivant as well as histone deaceylase inhibitors and an application in treating lung cancer, pancreatic cancer, colon cancer, liver cancer, prostatic cancer, kidney cancer, gastric cancer, brain tumor, sarcoma, ovarian cancer, breast cancer or glioma. The pharmaceutical composition provided by the invention has obvious synergistic effect, which improves the curative effect of medicine, reduces the dosage and also reduces the risk of side effect.

The invention provides a medicine for jointly treating malignant cerebroma and breast cancer by combining gene therapy with chemotherapy, and a preparation method thereof. The medicine for jointly treating cell growth of cerebral gliomas and breast cancer is formed by taking polyamide-amine treelike molecules as a carrier and applying antisense mini RNA-21 genes combined with taxol as a chemotherapeutic drug. The preparation method comprises the following steps that: polyamide-amine is dissolved in a buffer solution and prepared into a solution A; as-miR-21 as a therapeutic gene is dissolved in the buffer solution and prepared into a solution B; the taxol is dissolved in a solution and prepared into a solution C; and the solution A and the solution B are mixed well and then added with the solution C at room temperature. Compared with the prior chemotherapy and individual gene therapy, combined medical treatment has the advantages of obviously strengthening the sensitivity of tumor cells to chemotherapeutic drugs, lowering the survival rate of the cells, increasing apoptosis percentage, obviously increasing the number of S-period cells, remarkably reducing the migration capability of the cells and inhibiting tumors more effectively.

The present invention relates to a novel N-phenyl-2-pyrimidine-amine derivative represented by the above formula (1) and its salt showing a superior effect on cancer in warm-blooded animals, such as lung cancer, gastric cancer, colon cancer, pancreatic cancer, hepatoma, prostatic cancer, breast cancer, chronic or acute leukemia, hematologic malignancy, encephalophyma, bladder cancer, rectal cancer, cervical cancer, lymphoma, etc. The present invention also relates to a process for preparing the compound, and to a pharmaceutical composition for the treatment of the above various diseases, which comprises an effective amount of the compound as an active ingredient together with pharmaceutically acceptable inert carriers.

The present invention relates to a novel N-phenyl-2-pyrimidine-amine derivative represented by the above formula (1) and its salt showing a superior effect on cancer in warm-blooded animals, such as lung cancer, gastric cancer, colon cancer, pancreatic cancer, hepatoma, prostatic cancer, breast cancer, chronic or acute leukemia, hematologic malignancy, encephalophyma, bladder cancer, rectal cancer, cervical cancer, lymphoma, etc. The present invention also relates to a process for preparing the compound, and to a pharmaceutical composition for the treatment of the above various diseases, which comprises an effective amount of the compound as an active ingredient together with pharmaceutically acceptable inert carriers.

The invention relates to a medicament composition containing sorafenib, hepatocyte growth factor receptor (cMet) inhibitors and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and application thereof in preparing medicaments for treating lung cancer, colon cancer, liver cancer, kidney cancer, stomach cancer, encephaloma, sarcoma, pancreatic cancer, ovarian cancer, breast canceror prostatic cancer. The medicament composition has remarkable synergistic effect, improves the curative effect of the medicament, decreases the administration dosage and reduces the occurrence of side effects.

The invention relates to application of a PPAR delta inhibitor combined immunotherapy drug in preparation of antitumor drugs. The immunotherapy drug is an immune agonist or an immune checkpoint inhibitor. The tumors are preferably melanoma, breast cancer, ovarian cancer, pancreatic cancer, lung cancer, liver cancer, esophageal cancer, colorectal cancer, colon cancer, lymphoma, brain tumor, sarcoma, cervical cancer, prostate cancer, bladder cancer, osteosarcoma, head and neck cancer, renal cell cancer or gastric cancer. The medicine disclosed by the invention is remarkable in anti-tumor effect, high in targeting property and very small in side effect.

The invention discloses a medicament for treating malignant tumors, and relates to the technical field of traditional Chinese medicines. The medicament is prepared by processing oldenlandia diffusa, sculellaria barbata, poria cocos, fructus arctii, achyranthes and atorvastatin calcium as raw materials according to the requirements of compatibility, and the medicament is preferably prepared into capsules and tablets. The pharmaceutical composition has certain symptom relieving, tumor shrinkage and tumor growth inhibition effects and the like on various malignant tumors such as lung cancers, liver cancers, gastric cancers, colorectal cancers, breast cancers, brain tumors and lymph cancers, can enhance the human immunity and prolong the lives of patients with tumors, and can effectively relieve adverse reactions such as leukopenia, dizziness, tireness, power leakage, emaciation, poor stomach intake and nausea and vomiting caused by the radiotherapy and chemotherapy of tumors.

The invention relates to the field of antineoplastic medicines and provides a betulinic acid analogue with the structure shown in figure (1) or solvate thereof. The definition of R1, R2, X and n is inThe invention relates to the field of antineoplastic medicines and provides a betulinic acid analogue with the structure shown in figure (1) or solvate thereof. The definition of R1, R2, X and n is inthe specification. The invention also provides the a preparation method of the betulinic acid analogue with the structure shown in figure (1) or the solvate thereof, and the applications of pharmaceu the specification. The invention also provides the a preparation method of the betulinic acid analogue with the structure shown in figure (1) or the solvate thereof, and the applications of pharmaceutical compositions containing the betulinic acid analogue or the solvate thereof and medicines using the betulinic acid analogue or the solvate thereof as the effective constituent for preparing antintical compositions containing the betulinic acid analogue or the solvate thereof and medicines using the betulinic acid analogue or the solvate thereof as the effective constituent for preparing antineoplastic medicines for treating pulmonary cancer, prostatic cancer, colon cancer, leukemia, mammary cancer, liver cancer, gastric cancer, pancreatic cancer, malignant neuroglioma, cerebral tumor, andeoplastic medicines for treating pulmonary cancer, prostatic cancer, colon cancer, leukemia, mammary cancer, liver cancer, gastric cancer, pancreatic cancer, malignant neuroglioma, cerebral tumor, andthe like. the like.

The invention relates to a busulfan sustained-release implant for the treatment of solid tumors, which is characterized in that the sustained-release implant contains anti-cancer effective amount of busulfan, sustained-release excipient and certain amount of sustained-release regulator. The sustained-release excipient mainly comprises one or the combination of the copolymer of glycolic acid and hydroxyacetic acid, polifeprosan and poly (L-lactide-co-propyl phosphate). The invention can slowly release the busulfan in the local part of the tumor during the degradation and absorption process, so the invention can maintain effective drug concentration at the local part of the tumor at the same time of significantly reducing systemic toxic reaction. The sustained-release implant is arranged at the local part of the tumor, which can not only reduce the systemic toxic reaction of busulfan, but can also selectively improve the drug concentration at the local part of the tumor and strengthen the treatment effects of chemotherapy drugs, radiation therapy and other non-surgical therapies. The solid tumors include pancreatic cancer, lung cancer, liver cancer, breast cancer, brain tumor, ovarian cancer, prostate cancer, esophageal cancer, lymphoma, osteosarcoma, colorectal cancer and so on.

The invention relates to a drug compound of apigenin, apigenin-like derivants, artemisinin and artemisinin-like derivants and application thereof in the preparation of drugs for curing lung cancer, pancreas cancer, colon cancer, liver cancer, prostate gland cancer, kidney cancer, stomach cancer, encephaloma, sarcoma, ovarian cancer or breast cancer. The drug compound has a remarkable coordination effect, improves the curative effect of the drugs, reduces the drug dosage, and reduces the side effects.

The present invention relates to an N-phenyl-2-pyrimidine-amine derivative showing a superior effect on lung cancer, gastric cancer, colon cancer, pancreatic cancer, hepatoma, prostatic cancer, breast cancer, chronic or acute leukemia, hematologic malignancy, encephalophyma, bladder cancer, rectal cancer, or cervical cancer, etc. of warm-blooded animals and its salt. The present invention also relates to a process for preparing the compound, and to a pharmaceutical composition for the treatment of the above various diseases, which comprises an effective amount of the compound as an active ingredient together with pharmaceutically acceptable inert carriers.

The invention relates to a pharmaceutical composition containing a hepatocyte growth factor receptor (cMet) inhibitor and a histone deacetylase (HDAC) inhibitor, and application of the pharmaceutical composition in the preparation of medicaments for treating intestinal cancer, sarcoma, glioma, liver cancer, lung cancer, stomach cancer, brain tumors, pancreatic cancer, ovarian cancer, mammary cancer or prostate cancer. The pharmaceutical composition has significant synergistic effect, improves the treatment effect of the medicaments, reduces the administration dose and reduces side effects.

The invention provides a 2-(substituted benzene matrix) aromatic formic acid FTO inhibitor, a preparation method and application thereof. Specifically, the invention discloses a 2-(substituted benzenematrix) aromatic formic acid compound as shown in a general formula (I) and a pharmacologically acceptable salt, a hydrate or a solvate. The 2-(substituted benzene matrix) aromatic formic acid compound can be used as an inhibitor of an FTO target to treat diseases related to the FTO target, such as obesity, metabolic syndrome (MS), Type 2 diabetes (T2D), Alzheimer's disease, breast cancer, smallcell lung cancer, human bone marrow rhabdomyosarcoma, cancer of pancreas, and malignant glioma. The formula is shown in the description.

The invention relates to the field of a drug related to anti-tumor, provides a bicyclic fused heterocyclic compound or pharmaceutically acceptable salts thereof, also provides a preparation method of the bicyclic fused heterocyclic compound or the pharmaceutically acceptable salts thereof, a pharmaceutical composition and application thereof as active ingredient in preparation of anti-tumor drugs for treating small cell lung cancers, breast cancers, liver cancers, colon cancers, malignant gliomas, brain tumors, leucocythemia or pancreatic cancer and the like.

The present invention relates to compounds with a structure shown as a formula I or pharmaceutically acceptable salts thereof. R1, R2, R3, R4, R5 and R6 are defined as in the specification. The invention also provides a preparation method of the compounds with a structure shown as the formula I or pharmaceutically acceptable salts thereof, pharmaceutical compositions containing the compounds and pharmaceutically acceptable salts thereof, and application of betulinic acid analogues or solvates thereof as active ingredients to preparation of antineoplastic medicaments for treating lung cancer, prostate cancer, colon cancer, leukemia, breast cancer, liver cancer, gastric cancer, pancreatic cancer, human malignant glioma and brain tumor.

The invention relates to a pharmaceutical composition containing artemisinin, artemisinin derivatives and a Bcl-2 inhibitor and application of the pharmaceutical composition in preparing medicines used for treating colorectal carcinoma, liver cancer, lung cancer, kidney cancer, stomach cancer, brain tumor, sarcoma, pancreas cancer, ovarian cancer, breast cancer or prostate cancer. The pharmaceutical composition provided in the invention has a remarkable synergistic effect, improves curative effects of drugs and reduces administration dosage and possibility of occurrence of side effects.

The invention discloses a polyethylene glycol-gambogic acid liposome, which is composed of a polyethylene glycol-gambogic acid conjugate, polyethylene glycol, vitamin E, cholesterol and phospholipid in a weight ratio of 1-10:0.5-2:0.05-0.2:1-4:10-30. According to the invention, an amphiphilic polymer PEG and an antitumor drug gambogic acid are connected with an ester bond into a conjugate amphipathic PEG-GA, and the PEG-GA is inserted into a liposome bimolecular layer to construct a nano targeted drug delivery system, the water solubility of the drug can be improved, also the drug stability and antitumor effect can be enhanced, drug accumulation in normal tissue can be reduced, the survival time of tumor-bearing mice is prolonged, the treatment efficacy is improved and the toxic and side effects are reduced. The invention also provides a preparation method and application of the liposome, and the liposome can be applied to treatment of lung cancer, ovarian cancer, breast cancer, colorectal cancer, melanoma, head and neck cancer, lymphoma or brain tumors.

The invention relates to the field of organic synthesis and pharmaceutical chemistry and particularly relates to a series of compounds, and a preparation method and an anti-tumor application thereof.The invention discloses the series of compounds with anti-tumor activity, the preparation method of the compounds and the application of the compounds for preparing anti-tumor drugs. The formulae of the series of compounds are shown in the description. The series of compounds are synthesized by means of an organic synthesizing method. Activity tests find that the series of compounds have strong anti-tumor activity, and have an application prospect in preparing anti-tumor drugs. The compound 21# has wide inhibiting action on tumors, for example, liver cancer, lung cancer, gastric cancer, intestinal cancer, breast cancer, lymphoma, kidney cancer, pancreatic cancer, ovarian cancer, prostatic cancer, brain tumor, sarcoma, carcinoma of urinary bladder, melanoma and the like, and has a very goodapplication prospect.

The invention relates to a pharmaceutical composition containing a hepatocyte growth factor receptor (cMet) inhibitor and a histone deacetylase (HDAC) inhibitor, and application of the pharmaceuticalcomposition in the preparation of medicaments for treating intestinal cancer, sarcoma, glioma, liver cancer, lung cancer, stomach cancer, brain tumors, pancreatic cancer, ovarian cancer, mammary cancer or prostate cancer. The pharmaceutical composition has significant synergistic effect, improves the treatment effect of the medicaments, reduces the administration dose and reduces side effects.

The invention belongs to the technical field of biological medicines, and particularly discloses a compound and application thereof. The tumors include but are not limited to breast cancer, bladder cancer, colorectal cancer, liver cancer, lung cancer, lymphoma, myeloma, leukemia, melanoma, brain tumor, pancreatic cancer, prostate cancer, kidney cancer, ovarian cancer, head and neck cancer, nasopharynx cancer, esophagus cancer, gallbladder cancer, bile duct cancer, cervical cancer, stomach cancer, mesothelioma, glioblastoma, neuroblastoma, uterine cancer and thyroid cancer. , sarcoma, skin cancer, osteoma, osteosarcoma, testicular cancer, spermatocytoma, ureteral tumor, chorioepithelial cancer, and the like. In-vivo tumor pharmacological experiments prove that the compound disclosed by the invention has an obvious broad-spectrum anti-tumor effect.

The invention provides application of a thiophene compound in preparing medicaments for resisting tumors. The tumors comprise cerebroma, lung cancer, liver cancer, mammary cancer, prostatic cancer, pancreatic cancer, cervical cancer, stomach cancer, esophageal cancer and the like. The results of screenings on anti-tumor actions and cancer chemical prophylaxis performed by an MTT method show that the thiophene compound is concentration-dependent to inhibit the multiplication of tumor cells and can remarkably induce the expression of quinone reductase; and the results of a research on anti-inflammatory actions performed by a Westernblot method show that the thiophene compound can remarkably inhibit the expression of NFkappaB. The thiophene compound can also be applied to preparing cancer chemical prophylaxis medicaments, anti-inflammatory medicaments and the medicaments for inhibiting the generation of tumor vessels.

The invention provides a drug for treating cancer and inflammation. The drug is prepared from the following raw materials in parts by weight: 20-30 parts of radix angelicae sinensis, 15-20 parts of herba artemisiae annuae, 20-30 parts of herba salviae chinensis, 15-30 parts of radix isatidis, 15-30 parts of herba clerodendri cyrtophylli, 25-40 parts of radix scrophulariae, 15-20 parts of scolopendra, 10-15 parts of radix astragali, 10-20 parts of honeycomb, 15-25 parts of fructus trichosanthis and 20-50 parts of radix ginseng sinensis. The drug provided by the invention can be used for treating multiple cancers such as oral cancer, gastric cancer, liver cancer, esophagus cancer, lymph cancer, brain tumor, lung cancer, nasopharynx cancer, breast cancer, kidney cancer, bladder cancer and prostate cancer, and can adapt to various early, medium-term and later malignant tumors; through the clinical tests of some patients suffering from the malignant tumors, the drug has a reliable curativeeffect and a definite pharmaceutical effect in formula, generates effects quickly, and is low in cost and relatively small in toxic and side effects.